Literature DB >> 19948977

Choice of reperfusion strategy at hospitals with primary percutaneous coronary intervention: a National Registry of Myocardial Infarction analysis.

Reza Fazel1, Harlan M Krumholz, Eric R Bates, William J French, Paul D Frederick, Brahmajee K Nallamothu.   

Abstract

BACKGROUND: Many hospitals with percutaneous coronary intervention (PCI) capability also use fibrinolytic therapy in patients with ST-segment elevation myocardial infarction, but factors influencing the choice of reperfusion strategy at these hospitals are poorly understood. We examined clinical and system-related factors associated with choice of reperfusion strategy in patients with ST-segment elevation myocardial infarction at PCI-capable hospitals. METHODS AND
RESULTS: We analyzed patients with ST-segment elevation myocardial infarction who presented to PCI-capable hospitals between July 1, 2000, and December 31, 2006, in the National Registry of Myocardial Infarction. Hierarchical multivariable logistic regression was used to examine the association between choice of reperfusion strategy and patient-, hospital-, and system-related factors. We identified 25 579 patients who received primary PCI and 14 332 patients who received fibrinolytic therapy at 444 PCI-capable hospitals. Use of reperfusion strategies varied widely across hospitals, although primary PCI use increased over the study period. Among the key clinical factors that favored primary PCI, cardiogenic shock and delayed presentation were associated with greater use of primary PCI (adjusted odds ratios 2.14 [95% confidence interval 1.72 to 2.66] and 1.18 [95% confidence interval 1.09 to 1.27], respectively), whereas a Thrombolysis in Myocardial Infarction risk score >/=5 was not. In contrast, female gender, advanced age, and nonwhite race, all risk factors for intracranial hemorrhage after fibrinolytic therapy, were not associated with increased use of primary PCI. Off-hours presentation had the strongest association overall, with an approximately 70% lower likelihood of patients undergoing primary PCI (adjusted odds ratio 0.27, 95% confidence interval 0.25 to 0.29).
CONCLUSIONS: Use of primary PCI, although increasing over recent years, is not universal at PCI-capable hospitals, and optimization of its use at such hospitals represents a potential opportunity to improve outcomes in patients with ST-segment elevation myocardial infarction.

Entities:  

Mesh:

Year:  2009        PMID: 19948977     DOI: 10.1161/CIRCULATIONAHA.109.860544

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  5 in total

1.  Interventional cardiology: How should the appropriateness of PCI be judged?

Authors:  Gregg W Stone; Jeffrey W Moses
Journal:  Nat Rev Cardiol       Date:  2011-09-06       Impact factor: 32.419

2.  Identifying patients with refusal of percutaneous coronary intervention for acute myocardial infarction: a classification and regression tree analysis.

Authors:  Manyan Wu; Long Li; Sufang Li; Yuxia Cui; Dan Hu; Junxian Song; Chongyou Lee; Hong Chen
Journal:  Intern Emerg Med       Date:  2019-04-04       Impact factor: 3.397

3.  Case definitions for acute myocardial infarction in administrative databases and their impact on in-hospital mortality rates.

Authors:  Amy Metcalfe; Annabelle Neudam; Samantha Forde; Mingfu Liu; Saskia Drosler; Hude Quan; Nathalie Jetté
Journal:  Health Serv Res       Date:  2012-06-28       Impact factor: 3.402

Review 4.  New horizons of acute myocardial infarction: from the Korea Acute Myocardial Infarction Registry.

Authors:  Ki Hong Lee; Myung Ho Jeong; Youngkeun Ahn; Myeong Chan Cho; Chong Jin Kim; Young Jo Kim
Journal:  J Korean Med Sci       Date:  2013-01-29       Impact factor: 2.153

5.  Effects of no-reflow phenomenon on ventricular systolic synchrony in patients with acute anterior myocardial infarction after percutaneous coronary intervention.

Authors:  Le Wang; Gang Liu; Jun Liu; Mingqi Zheng; Liang Li
Journal:  Ther Clin Risk Manag       Date:  2016-06-24       Impact factor: 2.423

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.